eoadjuvant chemoradiation combined with gemcitabine and cisplatin for biliary tract cancer
Not Applicable
Recruiting
- Conditions
- resectable biliary tract cancer
- Registration Number
- JPRN-UMIN000020964
- Lead Sponsor
- Osaka Medical Center for Cancer and Cardiovasuclar diseasese
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
R2 resection Estimated remnant liver volume would be less than 35% Active double cancer
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Synergistic mechanisms gemcitabine cisplatin radiation DNA damage response biliary tract cancer cells
Neoadjuvant gemcitabine cisplatin chemoradiation versus upfront surgery resectable cholangiocarcinoma survival R0 resection
Predictive biomarkers gemcitabine cisplatin chemoradiation response resectable biliary tract cancer genomics proteomics
Toxicity management strategies neoadjuvant gemcitabine cisplatin chemoradiation biliary tract cancer patients
Emerging neoadjuvant regimens targeted therapy combinations resectable biliary tract cancer clinical trials